Criteria to qualify for study: Drug used in study:
  • R/R AML or MDS

HR 61

A Phase 1 Study of SEA-CD70 as monotherapy or in combination, in AML or MDS

  • High-risk AML or MDS; ECOG 0 or 1

BMT 30

Graft-versus-tumor augmentation with Nivolumab for high risk patients with MDS and AML after Allogeneic Stem Cell Transplantation using post transplantation Cyclophosphamide.